SEC Form 4 · accession 0001562180-18-003131
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas A Saccomano
Officer — CSO
Period of report
Jun 27, 2018
Accepted (ET)
Jun 29, 2018 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 27, 2018 | M | 11,453 | $0.00 | A | 66,731 | D | |
| Common Stock | Jun 27, 2018 | F | 5,038 | $18.50 | D | 61,693 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3 | $0.00 | Jun 27, 2018 | M | 11,453 | D | — | Aug 18, 2018 | Common Stock | 11,453 | 0 | D |
Explanation of responses
- F1Represents shares released on vesting of Restricted Stock Units ("RSUs") granted to the reporting person on August 18, 2014. The grant of these RSUs was previously reported on Table II.
- F2Represents shares withheld to satisfy tax withholding obligations of the reporting person.
- F3RSUs representing 11,453 shares of common stock vested upon the achievement of a second milestone relating to the return of rights to binimetinib to the Issuer on or prior to the fourth anniversary of the grant date, subject to continued service with the Issuer as of the vesting date.